Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 2:50 PM ET

Pharmaceuticals

Company Overview of Actavis Pharma, Inc.

Company Overview

Actavis Pharma, Inc. develops, manufactures, and markets generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. The company was formerly known as Schein Pharmaceutical, Inc. The company was founded in 1931 and is based in Parsippany, New Jersey. As of August 28, 2000, Actavis Pharma, Inc. operates as a subsidiary of Actavis plc.

Morris Corporate Center III

400 Interpace Parkway

Parsippany, NJ 07054

United States

Founded in 1931

1,325 Employees

Key Executives for Actavis Pharma, Inc.

Senior Vice President of Strategic Development
Age: 61
Senior Vice President of Technical Operations
Age: 68
Other Professional
Age: 65
Other Professional
Other Professional
Age: 72
Compensation as of Fiscal Year 2014.

Actavis Pharma, Inc. Key Developments

Galena Biopharma's Partner Orexo Files Patent Infringement Suit Against Actavis Laboratories, Andrx Corporation, Actavis, Inc. and Actavis Pharma

Galena Biopharma (GALE) announced that its partner Orexo has filed a patent infringement lawsuit in United States District Court for the District of New Jersey, against Actavis Laboratories, Andrx Corporation, Actavis Inc. (ACT) and Actavis Pharma for seeking to market a generic version of its Abstral drug. The lawsuit was filed in response to an Abbreviated New Drug Application filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Abstral sublingual tablets in the U.S. prior to the expiration of Orexo's U.S. patents.

Supernus Pharmaceuticals, Inc. Sues Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. for Infringement of Three Patents

Supernus Pharmaceuticals, Inc. announced that it sued Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (collectively 'Actavis') for infringement of three patents covering its antiepileptic drug Trokendi XR(R). Supernus' United States Patents Nos. 8,298,576, 8,298,580, and 8,663,683 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR(R) does not expire until 2029. The Complaint--filed in the U.S. District Court for the District of New Jersey--alleges that Actavis infringed Supernus' Trokendi XR(R) patents by submitting to the Food and Drug Administration an Abbreviated New Drug Application ('ANDA') seeking to market a generic version of Trokendi XR(R) prior to the expiration of Supernus' patents. Filing its Complaint within 45 days of receiving Actavis' Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Actavis' ANDA for 30 months.

Actavis Pharma Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Actavis Pharma reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net revenues of $2,264.9 million compared to $1,664.5 million a year ago. Adjusted gross profit was $1,406.2 million compared to $883 million a year ago. Net revenue increased 36% due to the acquisition of Warner Chilcott, new product launches, and higher international net revenue. Adjusted gross margin as a percentage of adjusted net revenues within Actavis Pharma increased to 65.3% in the first quarter of 2014 from 52.7% in the first quarter of 2013, as a result of the acquisition of Warner Chilcott in the fourth quarter of 2013. Adjusted net revenues were $2,152.82 million compared to $1,674.3 million a year ago.

Similar Private Companies By Industry

Company Name Region
Cambrex Bioscience Hopkinton Inc. United States
Cloud Pharmaceuticals, Inc. United States
Eisai Research Institute Of Boston, Inc. United States
Auxano Biologics, Ltd. United States
Neurion Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Actavis Pharma, Inc., please visit www.actavis.com/en/Global+Business/Generics/default.htm. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.